QIAGEN (QGEN)
(Delayed Data from NYSE)
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:36 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:36 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research
by Zacks Equity Research
QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.
QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays
by Zacks Equity Research
QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.
QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.
Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2.04% and 0.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Techne (TECH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay
by Zacks Equity Research
QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.
Charles River (CRL) Launches LVV-based Gene Therapy Platform
by Zacks Equity Research
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
by Zacks Equity Research
QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
by Zacks Equity Research
QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.
Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed
by Zacks Equity Research
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2% and 0.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
by Zacks Equity Research
QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.
Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?
by Zacks Equity Research
Emergent Biosolutions (EBS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
QIAGEN (QGEN) Expands Digital PCR Offering With New Pact
by Zacks Equity Research
QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.
Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.
QGEN vs. LFCR: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. LFCR: Which Stock Is the Better Value Option?
QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod
by Zacks Equity Research
QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.